<SEC-DOCUMENT>0001144204-15-003304.txt : 20150122
<SEC-HEADER>0001144204-15-003304.hdr.sgml : 20150122
<ACCEPTANCE-DATETIME>20150122170013
ACCESSION NUMBER:		0001144204-15-003304
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150122
FILED AS OF DATE:		20150122
DATE AS OF CHANGE:		20150122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Dehaier Medical Systems Ltd
		CENTRAL INDEX KEY:			0001474627
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34661
		FILM NUMBER:		15542554

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 501, JIUZHOU PLAZA
		STREET 2:		83 FUXING ROAD,
		CITY:			HAIDIAN DISTRICT, BEIJING
		STATE:			F4
		ZIP:			100856
		BUSINESS PHONE:		(8610) 5166-0080

	MAIL ADDRESS:	
		STREET 1:		SUITE 501, JIUZHOU PLAZA
		STREET 2:		83 FUXING ROAD,
		CITY:			HAIDIAN DISTRICT, BEIJING
		STATE:			F4
		ZIP:			100856
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v399261_6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>U.S. SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the month of January 2015</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Commission File Number: 001-34661</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Dehaier Medical Systems Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Dehaier Medical Systems Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Room 501, 83 Fuxing Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Haidian District, Beijing 100856</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">People&rsquo;s Republic of China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address of principal executive offices)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">Form 20-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Cautionary Note Regarding
Forward-Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Report, including
the exhibits included herein, may contain forward-looking statements.&nbsp;&nbsp;We have based these forward-looking statements
on our current expectations and projections about future events.&nbsp;&nbsp;Our actual results may differ materially from those
discussed herein, or implied by, these forward-looking statements.&nbsp;&nbsp;Forward-looking statements are generally identified
by words such as &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;plan,&rdquo; &ldquo;project&rdquo; and other similar expressions. In addition, any statements that refer to expectations
or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements included
in this Report are subject to significant risks and uncertainties,&nbsp;including but limited to:&nbsp;risks and uncertainties&nbsp;associated
with the integration of the assets and operations we have acquired and may acquire in the future; our possible inability to raise
or generate additional funds that will be necessary to continue and expand our operations; our potential lack of revenue growth
and other factors&nbsp;detailed in the Company&rsquo;s filings with the Securities and Exchange Commission. These forward-looking
statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond
the Company&rsquo;s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as
a result of new information, future events or otherwise, except as required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
January 22, 2015, Dehaier Medical Systems Limited issued a press release announcing that its representatives recently participated
in the Jiangxi Province Sleep and Health Forum to promote the Company&rsquo;s wearable sleep respiratory product and solution.
A copy of the press release is attached as Exhibit&nbsp;99.1 hereto and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Press Release dated January 22, 2015.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48.95pt">Pursuant to the requirements of the Securities
and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt"><FONT STYLE="font-size: 10pt"><B>DEHAIER MEDICAL SYSTEMS LIMITED</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 57%; padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 41%; padding-right: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt"><FONT STYLE="font-size: 10pt">January 22, 2015</FONT></TD>
    <TD STYLE="padding-right: 5.4pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Ping Chen</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Ping Chen</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Chief Executive Officer</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Principal Executive Officer) and</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Duly Authorized Officer</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-size: 10pt">Press Release dated January 22, 2015.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v399261_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;<IMG SRC="image_001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Dehaier Medical Systems Showcases its
Wearable Sleep Respiratory Solution at Jiangxi Sleep and Health Forum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">BEIJING, January 22, 2015 -- Dehaier Medical
Systems Ltd. (Nasdaq: DHRM) (&quot;Dehaier&quot; or the &quot;Company&quot;), which develops, markets and sells medical devices
and wearable sleep respiratory products in China, today announced that representatives from the Company recently participated in
the Jiangxi Province Sleep and Health Forum (the &ldquo;Jiangxi Sleep Forum&rdquo;) to promote the Company&rsquo;s wearable sleep
respiratory product and solution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Hosted by the Jiangxi Science and Technology
Association and the Jiangxi Sleep Medical Association, the Jiangxi Sleep Forum brought together over 100 attendees from leading
hospitals, businesses, government, and academia to discuss the latest advances in respiratory care and sleep medicine, including
obstructive sleep apnea syndrome (OSAS) diagnosis and treatment. The Company&rsquo;s wearable sleep respiratory solution systems
were featured at the Jiangxi Sleep Forum and garnered positive reviews from attending sleep experts from leading hospitals including
the Departments of Neurology and Cardiology of the Second Affiliated Hospital of Nanchang University (SAHNU) and the Affiliated
Hospital of Jiujiang College.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">According to epidemiological statistics, approximately
25% of people aged 40 years and over suffer from OSAS in China, and over 5% of people aged 40 years and over suffer from severe
OSAS symptoms. Patients with cardiovascular and cerebrovascular diseases have a particularly high rate of OSAS, which can be as
high as 70-80% for patients with refractory hypertension and cerebral stroke. Conversely, the rate of hypertension for patients
with severe OSAS symptoms is 60 times higher than that for people without OSAS. As hypertension can also lead to heart diseases
and cerebral stroke, OSAS, hypertension, cerebral stroke and heart diseases can create a vicious circle that exacerbates symptoms
of these diseases. China has approximately 50 million people with OSAS symptoms, making China one of the world&rsquo;s largest
OSAS markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Ms. Reyna Dong, Marketing Director of Dehaier's
Sleep Respiratory Products Division stated, &ldquo;As we continue to heighten our sales and marketing efforts with significant
investments in expansion of direct sales representatives and third-party agents, we also view conferences and forums as important
venues to raise the awareness for our innovative sleep respiratory solution systems among respiratory care and sleep professionals
whose academic authority and influence can facilitate our market development. We view the Jiangxi market as one of the key regions
for our sleep respiratory business. While we already cooperate with SAHNU for a pilot sleep screening program for cerebral strokes,
we believe the Jiangxi Sleep Forum provides us with an important venue to showcase our wearable sleep respiratory product systems
and help to accelerate our penetration of the Jiangxi market.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Ms. Dong continued, &ldquo;China&rsquo;s wearable
medical devices market is projected to reach RMB 5.0 billion by 2017 with chronic disease care and diagnosis to grow the fastest
and to account for approximately 80% of the market by 2017. This favorable market trend gives us a significant tailwind for our
sleep respiratory business in years to come.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Dehaier Medical Systems Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Dehaier is an emerging leader in the development,
marketing and sale of medical products, including medical devices and wearable sleep respiratory products. The company develops
and assembles its self-branded medical devices and sleep respiratory products from third-party components. The company also distributes
products designed and manufactured by other companies, including medical devices from IMD (Italy), HEYER (Germany) and Timesco
(UK). Dehaier's technology is based on six patents and eleven software copyrights. More information may be found at http://www.dehaier.com.cn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Forward-looking Statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>This news release contains forward-looking
statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning
plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other
than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product
and service demand and acceptance, fulfillment of bids and contracts, changes in technology, economic conditions, the impact of
competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and
Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company,
are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking
statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances
after the date hereof.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For more information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Dehaier Medical Systems Limited</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Janice Wang</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+86 10-5166-0080</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">investors@dehaier.com.cn</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Weitian Investor Relations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tina Xiao</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+1-917-609-0333</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tina.xiao@weitian-ir.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!/`.$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`**JSW20C'WFQPH[]\?I4L,J3Q)+&<HPRI%%M+BNMB6BBB@84444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!12"H;B<P(&"
M;L_[07^=%@)JIWTS06IE'`'WF_NCUK!U;Q'>P`K;):HW8LS2M_WR@_K7(ZAX
MDUIB1)J5PB$$%5MXH1_X^Q/Z5M3H2D8SK1B='J&I>7DLQ5LD';RRD<D#U(^\
M/4$U#I'B;[)J&RX*"SG=5<J?EAD;[CC_`*9R=CV;BN&M=8\YVLYY&DDC3*,)
M0TDL2\]1QYB'E3W&10]SAF214E7:PV)PLJ,-S*/9A\Z>C`BNKZL[.)S^VUNC
MW2CI7!>&/%WFZ8VGS3B6]M@-L[])(/X93^'!_P!JNGM-3RRQRYSG'N#UP??N
M?2N*5.479G7&HI*Z->C-,5E=<J00>A%>:7GQ0G'Q#;PQ8Z?"T4>0]Q<2%,D#
M)Q_2H9:U/3J*\@\0?&B71[>-H]&@>:0\`7JR@`>NWD5HZ7\59[NVM6N-(@\Z
M4*2L=_'CD\8!YS[4KCLST[BBN!\<_$)_!=YI\0TU;Q+L<HDN)5.?[N.?\:AU
M_P"(M]8ZE9V>BZ#)?>?&LCR3R"%8]W13GH1WIA8]$HK@9OB)/:&);G0UB>3A
M?^)C#@D=<<UMZMXIM]#\(OKVI1?9]L6\0&0,2YZ*".#GVH"S.CHKROPK\4M9
MUZVEOYO"ER;`'9'+:L""V><EL"M35?BC!H=DMYJ?A_5;6V=@JRN$*L?08-*X
M69Z!Q17,:+XQM]<\*3^(;:RN8K6-))$68`-($&21[<5R>E_&-=7T^ZOK;09%
MM;7:)I9KN.-5+=!SUIA8]3HKSRV^)<UY;B>WT>W>(G`;^TX1_,UT/AWQ#=ZX
MTQETP6T*<+*ETDJLW]WY>AH"QT5%<3K'Q-T+2],OKU#/=BQN5MKA(EP5<Y]>
MO2L\_$76;[38;S1/!&K7238='E*JC(>X(-`6/1J2N*C\;ZJWEB3P/KR,V`Q"
MH0OKWZ5V2G..HXH$24444`%%%%`!5:[7=;L>.!GIFK--*AE(/3O0M!;G"ZQ"
MTD+`,Y0#)"!L?CRH_.N!O[G3;9RLEU;(_=?/7=^2*?YUW7Q!CM8X;"W\L8:1
MKB;))_=Q*6(^A.T?C7F;::JR?ZI=\*'Y5'!<#)'_`'\D`_"O6PB3C=L\^NVI
M6*SRMJDX_L='N;N`B13!%(Q0@]<GBHKW4I"$ACA>.[W86#&&1BV2F/\`9;YA
M[$BM[P9XD_X1;7;^..P%S;2,(MR'$AV#'RYX.3DXZUDW>O0ZEXGO]5FM#9W4
MS;=@X=!C&!GHY'5NPKK3E[1JVEM#!I<J=]6=#HW_`!*[4$O&)BYD=^J>8.3C
M_IG'DGT+D"NKTV_9V$7EL79A&(B?F9CR(R?7'SN>V0*X>SN#(!,7BC5%#@D?
MNXD7HQ']Q3]U>KMS7I7@S16CC35+N)XV*%;2&7ET0G+._P#TT<\GTX%>?B4H
MZLZJ-V[(ZFTMVMX@'<R2'[S=!GV'8>U>`ZVD]K\=KRVMYGD:[C:-FE&\@/&<
M@>@^E?1->.>*OA?XAU[XB3:W9:A#8VSA0LZN3(N%P<"O-9WQL>?:<D>@:1I\
M=Q%9M%97_P!K:XGM)!YF5QY;''3O5J+31JS:3;>7!;Q+J+78N(K*3+B1LA>G
MW1VKHH?AGXLT2XU+31#%KNBW\81UFNC&<CD,.NU@:7PKX(\<Z'XH@U*XT^.Y
MBB^2&.?4&*P+V.!UP,XI6*N3_'R=XY?#T*%4&]F$@&'4@@<-U%<;XO>>[^*$
M*W6G3S$PP@VKR;FG`CZG'7/7%>J?%+P)K'C*\T<Z<;=4MBWG22OC;DCH._2G
MZQ\)QK'BRWU_^W+BTFBCB3;`@R"BXR"?6FT),\%UJWM6\.07D-HZ^9=21_:&
M4*!@?<VCG(]:^CK.XTQ?AE8WWB#3T6TM+19&BN`&Z+P1]>WUK@/%'PKU_6=2
MAT^S:;[$DI9[NZF0H0?X@BC.?K7>>)_AZWB70]/T=M<NK6SM(U1XXT4B8J.&
M.:$@;/#]1UKQ#XF\+:O?FX^R:!;7$8BLHD"H&8G:JX]!R?K3;?4M:\/:!X=U
M"X:/4-#FE=EMIXPZJP;#KSW(Y%>J^+/`-]!X#M?"/AG3TG@>59)KF68*P<')
M)'?/Z5KZ=\-+9OAM;^%=9E$S(3(9H1@QN3G*_3/XTK!<V9;O3[_X=7-WI8C6
MQETZ1HEC&`HV'C`]*\8^$>EG5M`UF$:5::FZSQ,(+N0JF,'GZBO4?#W@&X\+
M^&-5TBVUB>^BN8)%@AG4*L;,".,>N:XSP=\//''AW2=4L$.G0K?!5>3SVW@#
MKM*]/2F!Q&LW]O<?$^&Z^Q:7;P6+QQR(AW6V5XP6`[]*^A_#37WD2&YTK3K&
MW?#PFQD#+)GOP![<UP>F?#S6-*T2[TF+2M!EM[PYG,\LCO)Z?-VQU%=/X&T#
M6_#EM)I]TUJ+!1F%$E>5E)[`MT4>E"!L\G\?Z>NC6GB>S@U.QN_M.H1W,L*;
MA-!UP&[8YKO-%\,:/J/PVTC5]1BNI)+72@V(;IX]P52<8!QGWKG?$_P_\02+
MK%C:6$NHW6JW:7$FI/(D<2J,G9MZC!/6O1(M*OM$^&L.BI;O>W:6)M2("/O%
M",\]LT`V>>?"'1Y]>UBY\3O?7,%E;3F.WL%N'9<X_BR>0`?SKW&N!^%'A/4_
M"7AB:TU58DN)K@R[$;=M&`!D^O%=_3);U"BBB@`HHHH`****`."\86SWNN;-
MN46WBA_[^2C=^B5R@ML!KAUXR)3Z?\M)C_[)7I-]9237,LWEMEFRO'91A?U8
MFLZ32%D7R5CX?*XQV("?^@J3792K<D;'+.FVVSQS2K*6*)2W+3C=L?!$F?[N
M?E?Z`AA6VMC:ZBOE7=NLNS@K(&8I]&'[Q/H017H^I?#^PF61M+863/R\!3?;
MR'_:C/\`,8-<_)X>U"QD2.ZLG$:'Y9$!N(A].DB?@2!72\7&?J8^PE'<JZ#X
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MY!`]12U'<YC1_%]T[Z_:ZK%;(^AHGF7"R$(Y*9^;/0U6\-^/[C6O%<.D-!;/
M!+9_:A<0AUVCL,-U!]:[%=(T]#>;;&#_`$T[KKY!^^.,?-Z\5!8>&]&TJ=IK
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M^[2W8`\-C&XD@`?6NTO?'&IZ7_8FDQVJ7FIW&G?;)Y'!/0=-J]R?PKNKG2;"
M\T[^SKFSAELMH40LORX'08]L57O?#ND:E)%)>:=!+)$NR-F7E5_N@^GM2L.Y
MRC^/K]XO#UNFG6\&H:K#)-(MQ+^[@1`23QUSBL.S\8:R_@#3+ZYN9)+[4]7\
MB)HVV[8]Y''M@5Z/=^'='OXH(KO3+>5+<8A#)]P>@]*4>'=(2VL[==-MQ#9/
MYEL@3B)O5?0T:A<P=0\5WR^+KC0M.M[(_8[>.>XENYB@)<C"KCH<=S5'Q?\`
M$)_#MQ?16RV4LEE`DLL+EV?YCT)'"^V<YKK;G0-)O=02_N=.MY;N/&V5DRPQ
MTJ+4/"VAZK<O<7^E6MQ,ZA7=TR6`Z`^M&HM#G3XCO[KQWX?L(Y1;VT^G->74
M)(/7``S[&NZXK'O?"^BZC<I=7FF6\MQ&@C21EY51T7/I6JHQ@!2!0!)1113`
M****`"BBB@`INT<'`X]J=10`4E+10!7%I%YPF"`2`8W#C/U]:L444>H@HHHH
K&%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
